Krystal Biotech, Inc. (KRYS) financial statements and ratios from SEC XBRL: revenue $389.13M (TTM), net margin 52.6%, revenue growth 33.9% YoY, P/E 40.5. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $389.13M |
| Net Margin | 52.6% |
| Revenue Growth (YoY) | 33.9% |
| EPS Growth (YoY) | 126.9% |
| FCF Growth (YoY) | 58.5% |
| P/E Ratio | 40.5 |
| EV / EBITDA | 44.8 |
| Price / Book | 7.34 |
| Price / Sales | 22.17 |
| FCF Yield | 4.1% |
| DCF Value (model) | $285.97 |
| DCF Upside vs Price | -15.1% |
| Altman Z-Score | 53.27 (safe) |
| Sector P/E (Healthcare) | 21.6 |
KRYS overview · KRYS earnings · KRYS KPIs · KRYS investor relations · KRYS ownership · KRYS peers · KRYS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.